Wyeth hit by drug ruling

US Credit magazine
01 Jul 2004

Tweet
Facebook
LinkedIn
Save this article
Send to
Print this page

Yield margins on bonds of New Jersey-based pharmaceuticals company Wyeth took a hammering in the secondary markets in May after a federal appeals court made it easier for people suing the company to present evidence suggesting they were harmed by two drugs in the company’s ‘fen-phen’ weight-loss cocktail. Hundreds of lawsuits have been filed against the company, and last month a Texas jury awarded $1.36 million to a woman who claimed her health was damaged by the slimming pills.

The

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to print this content. Please contact info@risk.net to find out more.

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

You already have an account with us*. Sign in below to continue.